The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Matrix Metalloproteinase Inhibitors as Investigative Tools in the Pathogenesis and Management of Vascular Disease
Open accessAbstract
Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade various components of the extracellular matrix (ECM). MMPs could also regulate the activity of several non-ECM bioactive substrates, and consequently affect different cellular functions. Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs and others. Pro-MMPs are cleaved into active MMPs, which in turn act on various substrates in the ECM and on the cell surface. MMPs play an important role in the regulation of numerous physiological processes including vascular remodeling and angiogenesis. MMPs may also be involved in vascular diseases such as hypertension, atherosclerosis, aortic aneurysm, and varicose veins. MMPs also play a role in the hemodynamic and vascular changes associated with pregnancy and preeclampsia. The role of MMPs is commonly assessed by measuring their gene expression, protein amount, and proteolyic activity using gel zymography. Because there are no specific activators of MMPs, MMP inhibitors are often used to investigate the role of MMPs in different physiologic processes and in the pathogenesis of specific diseases. MMP inhibitors include endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline and marimastat. MMP inhibitors have been evaluated as diagnostic and therapeutic tools in cancer, autoimmune and cardiovascular disease. Although several MMP inhibitors have been synthesized and tested both experimentally and clinically, only on MMP inhibitor, i.e. doxycycline, is currently approved by the Food and Drug Administration. This is mainly due to the undesirable side effects of MMP inhibitors especially on the musculoskeletal system. While most experimental and clinical trials of MMP inhibitors have not demonstrated significant benefits, some trials still showed promising results. With the advent of new genetic and pharmacological tools, disease-specific MMP inhibitors with fewer undesirable effects are being developed and could be useful in the management of vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Van Wart, H. E., & Birkedal-Hansen, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5578 · Cited by 1,475
Frisch, S. M., & Screaton, R. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00251-9 · Cited by 1,249
Regulation of matrix biology by matrix metalloproteinases
Mott, J. D., & Werb, Z. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.07.010 · Cited by 1,104
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., & Lipton, S. A. (2002) · Science · doi:10.1126/science.1073634 · Cited by 950
Ohuchi, E., Imai, K., Fujii, Y., Sato, H., Seiki, M., & Okada, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2446 · Cited by 938 · cited 2×
“MMP-23 has a unique C-terminal cysteine-rich domain and an immunoglobulin-like domain immediately after the C-terminus of the catalytic domain (Ohuchi et al., 1997; Holmbeck et al., 1999; Nagase et al., 2006; Cauwe et al., 2007) (Table 1).”
BackgroundBergan, J. J., Schmid-Schönbein, G. W., Smith, P. D. C., Nicolaides, A. N., Boisseau, M. R., & Eklof, B. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055289 · Cited by 933 · cited 1×
“One of the complications of VV is thrombophlebitis characterized by endothelial, vein wall and valve inflammation, and leukocytes infiltration leading to disruption of vein function and venous thrombosis (Takase et al., 2000; Sayer and Smith, 2004; Bergan et al., 2006).”
BackgroundNewby, A. C. (2005) · Physiological Reviews · doi:10.1152/physrev.00048.2003 · Cited by 817
In vivo molecular target assessment of matrix metalloproteinase inhibition
Bremer, C., Tung, C.-H., & Weissleder, R. (2001) · Nature Medicine · doi:10.1038/89126 · Cited by 726
Ilić, D., Almeida, E. A. C., Schlaepfer, D. D., Dazin, P., Aizawa, S., & Damsky, C. H. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.547 · Cited by 495
Hypochlorous Acid Oxygenates the Cysteine Switch Domain of Pro-matrilysin (MMP-7)
Fu, X., Kassim, S. Y., Parks, W. C., & Heinecke, J. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106958200 · Cited by 482 · cited 4×
“Also, elevated iron deposits in the lower limb may cause activation of MMPs and ROS and lead to impaired ulcer healing (Zamboni et al., 2005).”
BackgroundInfluentialThe Design of Inhibitors for Medicinally Relevant Metalloproteins
Jacobsen, F. E., Lewis, J. A., & Cohen, S. M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600204 · Cited by 132 · cited 2×
“These ZBGs have some features in common with hydroxamic acids but with better biostability and tighter Zn2+ binding due to ligand rigidity and, in some cases, the incorporation of sulfur donor atoms (Puerta and Cohen, 2003; Jacobsen et al., 2007).”
BackgroundNorgauer, J., Hildenbrand, T., Idzko, M., Panther, E., Bandemir, E., Hartmann, M., Vanscheidt, W., & Herouy, Y. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.05025.x · Cited by 101 · cited 1×
“MMP-2, MT1-MMP, MT2-MMP, and EMMPRIN (MMP activator) are elevated in venous ulcer compared to control dermis (Norgauer et al., 2002).”
BackgroundZamboni, P., Scapoli, G., Lanzara, V., Izzo, M., Fortini, P., Legnaro, R., Palazzo, A., Tognazzo, S., & Gemmati, D. (2005) · Dermatologic Surgery · doi:10.1097/00042728-200506000-00005 · Cited by 44
Cited by
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease
Wang, X., & Khalil, R. A. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.08.002 · Cited by 754
Self-citationThe Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
Chen, Q., Jin, M., Yang, F., Zhu, J., Xiao, Q., & Zhang, L. (2013) · Mediators of Inflammation · doi:10.1155/2013/928315 · Cited by 445
Increased metalloproteinase activity in the hippocampus following status epilepticus
Dubey, D., McRae, P. A., Rankin-Gee, E. K., Baranov, E., Wandrey, L., Rogers, S., & Porter, B. E. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.02.021 · Cited by 65
Metadata
- Authors
- Benjamin, M. M., & Khalil, R. A.
- Venue
- Experientia Supplementum
- Publisher
- Springer Basel
- Published
- 2012
- Volume
- 103
- Pages
- 209-279
- ISSN
- 1023-294X (ISSN-L)
- OpenAlex
- W1898684747
- Cited by
- 168
- References
- 17
- FWCI
- 62.52
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.